OncoMatch/Clinical Trials/NCT06410833
Belimumab After Rituximab in Resistant Primary Juvenile SS
Is NCT06410833 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Rituximab and Belimumab for sjogren's syndrome.
Treatment: Rituximab · Belimumab — The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome. Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS. Participants will: Recieve Rituximab each week for 2-4 times until B%\<0.5% or B#\<20×10\^6/L Recieve Belimumab 4 weeks after the last use of Rituximab, and then every 4 weeks until week 28
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Prior therapy
Must have received: immunosuppressant
Application of two or more immunosuppressants or prednisone +immunosuppressive therapy for more than 3 months
Cannot have received: anti-CD20 antibody (rituximab)
Exception: allowed if >6 months since last dose
Previously treated with rituximab within six months
Cannot have received: biologic therapy (belimumab, telitacicept)
previously treated with other biologics, including belimumab or Telitacicept
Lab requirements
Blood counts
wbc >= 1.5 × 10^9/l, neutrophils >= 1 × 10^9/l, igg >= 4 g/l, iga >= 0.1 g/l
Kidney function
egfr >= 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify